Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy (Q37704966)

22 August 2017

1 reference

title

Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy (English)

1 reference

Nestor F Gonzalez-Cadavid

22 August 2017

1 reference

series ordinal

1

object named as

Nestor F Gonzalez-Cadavid

1 reference

22 August 2017

2

Jacob Rajfer

1 reference

PubMed ID

20212516

22 August 2017

language of work or name

English

0 references

publication date

9 March 2010

1 reference

22 August 2017

Nature Reviews Urology

1 reference

22 August 2017

7

1 reference

22 August 2017

4

1 reference

22 August 2017

215-221

1 reference

https://scigraph.springernature.com/pub.10.1038/nrurol.2010.24

22 August 2017

0 references

cites work

NOS-2 mediates the protective anti-inflammatory and antifibrotic effects of the Th1-inducing adjuvant, IL-12, in a Th2 model of granulomatous disease

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Peyronie's disease: a critical appraisal of current diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Peyronie's disease intervention trials: methodological challenges and issues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Peyronie's disease: the epidemiology, aetiology and clinical evaluation of deformity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

A case-control study on risk factors for Peyronie's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Defining the clinical characteristics of Peyronie's disease in young men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Risk factors for Peyronie's disease: a case-control study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Experimental models of Peyronie's disease. Implications for new therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Peyronie's disease associated with increase in plasminogen activator inhibitor in fibrotic plaque.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Gene transfer of inducible nitric oxide synthase complementary DNA regresses the fibrotic plaque in an animal model of Peyronie's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Relationship between the severity of penile curvature and the presence of comorbidities in men with Peyronie's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Peyronie's disease: epidemiology and clinical presentation of 134 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

The effect of surgical trauma on rat tunica albuginea.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Immunologic findings in Peyronie's disease: a controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

The genetics and immunology of Peyronie's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Prospective Analysis of HLA Classes I and II Antigen Frequency in Patients With Peyronie’s Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

The significance of histopathological changes of the normal tunica albuginea in Peyronie's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Antifibrotic role of inducible nitric oxide synthase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

The myofibroblast: one function, multiple origins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Cell culture of Peyronie's disease plaque and normal penile tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Peyronie's disease cell culture models: phenotypic, genotypic and functional analyses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: implications for peyronie disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Mechanisms of calcification in Peyronie's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Cellular and molecular mechanisms of fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

An animal model of Peyronie's-like condition associated with an increase of transforming growth factor beta mRNA and protein expression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Histological and ultrastructural alterations in an animal model of Peyronie's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

A rat model of Peyronie's disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Profibrotic role of myostatin in Peyronie's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Repeated intratunical injection of adenovirus expressing transforming growth factor-beta1 in a rat induces penile curvature with tunical fibrotic plaque: a useful model for the study of Peyronie's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Case report: Avoidance of palpable corporal fibrosis due to priapism with upregulators of nitric oxide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

A new mouse model of Peyronie's disease: An increased expression of hypoxia-inducible factor-1 target genes during the development of penile changes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Effect of muscle-derived stem cells on the restoration of corpora cavernosa smooth muscle and erectile function in the aged rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Expanding the paradigm for plaque development in Peyronie's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Peyronie's disease fibroblasts demonstrate tumorigenicity in the severe combined immunodeficient (SCID) mouse model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Mechanisms of Disease: new insights into the cellular and molecular pathology of Peyronie's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Mechanisms of penile fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1beta and transforming growth factor-beta in Peyronie's plaque fibroblasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Gene expression profiles in the Peyronie's disease plaque

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Medical management of Peyronie's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Fibrosis, chronic inflammation and new pathways for drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

The pleiotropic effects of inducible nitric oxide synthase (iNOS) on the physiology and pathology of penile erection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Fibrosis and loss of smooth muscle in the corpora cavernosa precede corporal veno-occlusive dysfunction (CVOD) induced by experimental cavernosal nerve damage in the rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Interstitial fibrosis of unilateral ureteral obstruction is exacerbated in kidneys of mice lacking the gene for inducible nitric oxide synthase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Chronic diabetic nephropathy: role of inducible nitric oxide synthase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Deficiency of inducible nitric oxide synthase exacerbates hepatic fibrosis in mice fed high-fat diet

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Lack of inducible nitric oxide synthase leads to increased hepatic apoptosis and decreased fibrosis in mice after chronic carbon tetrachloride administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Enhanced oxidative stress in iNOS-deficient mice after traumatic brain injury: support for a neuroprotective role of iNOS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Inducible nitric-oxide synthase is an important contributor to prolonged protective effects of ischemic preconditioning in the mouse kidney.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

The ubiquitous role of nitric oxide in cardioprotection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Cardiac fibrogenesis following infarction in mice with deletion of inducible nitric oxide synthase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Proteinuria is reduced by inhibition of inducible nitric oxide synthase in rat renal ischemia-reperfusion injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Nitric oxide attenuates epithelial-mesenchymal transition in alveolar epithelial cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Pulmonary fibrosis in L-NAME-treated mice is dependent on an activated endothelin system.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Cyclic GMP kinase and RhoA Ser188 phosphorylation integrate pro- and antifibrotic signals in blood vessels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

NO signaling through cGMP in renal tissue fibrosis and beyond: key pathway and novel therapeutic target

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Histopathologically proven prevention of post-prostatectomy cavernosal fibrosis with sildenafil

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Effect of sildenafil administration on penile hypoxia induced by cavernous neurotomy in the rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Erectile dysfunction following prostatectomy: prevention and treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

PDE-5 inhibition impedes TSP-1 expression, TGF-beta activation and matrix accumulation in experimental glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Current pharmacological treatment of pulmonary arterial hypertension.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Treatment of erectile dysfunction in patients with Peyronie's disease using sildenafil citrate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.24

A retrospective review of 307 men with Peyronie's disease

31 March 2020

1 reference

12 December 2020

Scar contracture: cellular and connective tissue aspects in Peyronie's disease.

1 reference

12 December 2020

Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection

1 reference

12 December 2020

Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis

1 reference

12 December 2020

The myofibroblast: phenotypic characterization as a prerequisite to understanding its functions in translational medicine

1 reference

12 December 2020

The genetic inactivation of inducible nitric oxide synthase (iNOS) intensifies fibrosis and oxidative stress in the penile corpora cavernosa in type 1 diabetes

1 reference

12 December 2020

Proposal: trauma as the cause of the Peyronie's lesion

1 reference

12 December 2020

Fibrin deposition in Peyronie's disease plaque

1 reference

12 December 2020

Long-term continuous sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2010.24

1 reference

22 August 2017

1 reference

PubMed ID

20212516